Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I

Oct 27 2016

• By Sue Sutter

PS1610_Failed Executive_1200x675

Related Content

GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table

Jul 06 2015

GDUFA II? Mylan Lawyer Questions User Fee Law’s Future Absent FDA Progress

Apr 27 2015

GPhA Warns FDA On ANDA Review Transparency

Aug 13 2015

ANDA Approvals, Complete Responses Hit Record In FY 2016

Oct 12 2016

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Oct 24 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

GDUFA II: Industry Shares Stage With FDA

Oct 23 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Fresenius SE & Co. KGaA

Additional Topics

Policy Generic Drugs Drug Review BioPharmaceutical

More from Policy & Regulation

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window